Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Oxigene To Acquire Vaxgen In Stock Swap
by Rick Mullin
October 26, 2009
| A version of this story appeared in
Volume 87, Issue 43
Oxigene, a biopharmaceutical company developing treatments for cancer and eye diseases, will acquire VaxGen, a biopharmaceutical firm with cell culture and microbial biologic production expertise, in an exchange of common stock. The deal will give Oxigene a cash infusion of about $33 million. VaxGen suffered a setback in 2006 when it lost an $878 million contract to manufacture 75 million doses of an anthrax vaccine for the U.S. government.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter